Cooperation between SS18-SSX1 and miR-214 in Synovial Sarcoma Development and Progression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Synovial sarcoma pathogenesis is driven by SS18-SSX fusion proteins, but the underlying genetic network remains unclear.
• Understanding the mechanisms of synovial sarcomagenesis is crucial for developing targeted therapies.

Purpose of the Study:

• To establish a functional ex vivo mouse model for studying synovial sarcoma development.
• To investigate the genetic alterations and molecular pathways involved in SS18-SSX1-driven tumorigenesis.
• To identify novel therapeutic targets, particularly microRNAs, in synovial sarcoma.

Main Methods:

• Development of an ex vivo mouse model using retroviral gene transfer of SS18-SSX1 into mesenchymal cells.
• Subcutaneous transplantation into nude mice to induce tumor formation.
• Gene expression profiling, retroviral tagging for integration site analysis, and microRNA expression analysis.

Main Results:

• The SS18-SSX1 mouse model recapitulated key features of human synovial sarcoma, including invasive spindle cell proliferation and characteristic protein expression (Cytokeratin, TLE1, BCL2).
• SS18-SSX1 modulated the SWI/SNF pathway and upregulated TLE1 and ATF2.
• Frequent retroviral integrations at the DNM3 locus identified miR-199a2 and miR-214 upregulation; co-introduction of SS18-SSX1 and miR-214 accelerated sarcoma onset, implicating miR-214 as a cooperative oncomiR.

Conclusions:

• The established mouse model is a valuable tool for investigating synovial sarcoma.
• miR-214 acts as a cooperative oncomiR in synovial sarcomagenesis, promoting tumor development and progression via non-autonomous cytokine gene expression.
• Targeting miR-214 may offer a novel therapeutic strategy for synovial sarcoma.